Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
KNOXVILLE, Tenn., June 25, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, today announced the launch of its Veripure™ open science research program. Veripure makes PV-10, formulated from pharmaceutical-grade RBS API, freely available to qualified researchers globally witho
KNOXVILLE, Tenn., June 25, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, today announced the launch of its Veripure™ open science research program. Veripure makes PV-10, formulated from pharmaceutical-grade RBS API, freely available to qualified researchers globally without restrictive constraints on study direction, design, or findings. Researchers interested in studying RBS for therapeutic applications through the Veripure program are invited to contact Provectus directly at veripure@pvct.com.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.